Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker

Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker

Background: Elevated plasmatic lactate dehydrogenase (LDH) levels are associated with worse prognosis in various malignancies, including metastatic breast cancer (MBC). Nevertheless, no data are available on the prognostic role of LDH as a dynamic biomarker during first-line treatment in unselected...

Full description

Bibliographic Details
Main Authors: Giacomo Pelizzari, Debora Basile, Silvia Zago, Camilla Lisanti, Michele Bartoletti, Lucia Bortot, Maria Grazia Vitale, Valentina Fanotto, Serena Barban, Marika Cinausero, Marta Bonotto, Lorenzo Gerratana, Mauro Mansutti, Francesco Curcio, Gianpiero Fasola, Alessandro Marco Minisini, Fabio Puglisi
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Cancers
Subjects:
metastatic breast cancer
lactate dehydrogenase
serum biomarker
LDH
monitoring metastatic breast cancer
Online Access:https://www.mdpi.com/2072-6694/11/9/1243

Similar Items

Similar Items